Detail akcie Aethlon Medical Rg online

Business Summary: Aethlon Medical, Inc. is a clinical-stage medical device company. The Company is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.
Financial Summary: BRIEF: For the six months ended 30 September 2025, Aethlon Medical Inc revenues was not reported. Net loss decreased 40% to $3.2M. Lower net loss reflects Payroll and related expenses decrease of 55% to $1.2M (expense), General and administrative - Balancing v decrease of 33% to $1M (expense), Professional Fees decrease of 27% to $870K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$32.80 to -$12.23.